Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...
Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...
The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...
Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) is expected to issue its quarterly earnings data before the market ...
Understanding liver fibrosis progression through machine learning provides valuable insights into disease mechanisms, ...
Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback